Výsledky vyhledávání - "cost effectiviness"

Dissertation/ Thesis

Análise de custo-efetividade das medidas para prevenção e controle de infecções por Staphylococcus aureus resistente à oxacilina em unidade de terapia intensiva

Autor: Freitas, Marise Reis de [UNIFESP]

Publikováno v: Repositório Institucional da UNIFESPUniversidade Federal de São PauloUNIFESP.

Made available in DSpace on 2015-12-06T23:00:48Z (GMT). No. of bitstreams: 0 Previous issue date: 2000
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
O Staphylococcus aureus resistente a oxacilina (ORSA) e um dos pri

Externí odkaz: http://repositorio.unifesp.br/handle/11600/16635

Zobrazit plný text záznamu

Analysis the cost-effectiviness of an intervention to prevent infection caused by ORSA at intensive care unit

Autor: Freitas, Marise Reis de [UNIFESP]

Publikováno v: Repositório Institucional da UNIFESP
Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) O Staphylococcus aureus resistente a oxacilina (ORSA) e um dos principais agentes das infeccoes hospitalares em nosso meio. No Hospital São Paulo o ORSA e endemico, representando

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::6907c12cd2d2fa32ae218375676bc668
http://repositorio.unifesp.br/handle/11600/16635

Zobrazit plný text záznamu

Cost effectiviness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study

Autor: Andrew Street, Anthony G Threlfall, P. G. Warmerdam, Harry J. de Koning, Ciaran B J Woodman, Rob Boer, Ellis Friedman

Publikováno v: British Medical Journal, 317, 376-379. BMJ Publishing Group
EUR Research Portal
Scopus-Elsevier

Objective: To compare the cost effectiveness of two possible modifications to the current UK screening programme: shortening the screening interval from three to two years and extending the age of invitation to a final screen from 64 to 69. Design: C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2930eae47fa273e120fb92dfd3cd93ff
https://pure.eur.nl/en/publications/b8d64432-cfb3-4ce2-9d91-c238982bf3e6

Zobrazit plný text záznamu

Cost Effectiviness of Rituximab Given At Fixed Dose (1000 mg on days 1 and 15) Compared to the Standard Regimen in adult's Immune Thrombocytopenia

Autor: Bernard Bonnotte, Sylvain Audia, Marc Michel, Medhi Khellaf, Matthieu Mahévas, Bertrand Godeau, Nicolas Schleinitz, Mikael Ebbo, Corinne Haioun

Publikováno v: Blood. 120:2157-2157

Abstract 2157 Introduction: The chimeric monoclonal antibody directed against CD20 Rituximab (RTX), was initially developed to treat non-Hodgkin B-cell lymphoma. In ITP, B-cell depletion as a second line strategy has provided 40% of overall response

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::46a52dff00847104f221beaeeffc38e3
https://doi.org/10.1182/blood.v120.21.2157.2157

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání